WW International, Inc. (WW)
NASDAQ:WW
Want to see WW full AI Analyst Report?
Top Page
WW International, Inc.
(NASDAQ:WW)
Select Model
Select Model
Rating:55Neutral
Price Target:
$17.00
▼(-22.34% Downside)
Action:Reiterated
Date:06/01/26
The score is held back primarily by weak cash-flow performance and ongoing revenue declines despite improved profitability and leverage. Offsetting factors include inexpensive-looking valuation and improving near-term technical momentum, while the latest earnings call was constructive on guidance and Clinical traction but still flagged meaningful near-term risks (subscriber mix shift, cash usage, and interest burden).
Positive Factors
Clinical subscription growth & ARPU expansion
Sustained mix shift toward higher‑value Clinical subscribers and rising ARPU improves revenue per user and long‑run unit economics. As Clinical becomes a larger revenue share, the business can offset Behavioral declines, support margin expansion and increase lifetime value through upsells and tailored programs.
Negative Factors
Multi-year revenue decline & Behavioral erosion
A persistent multi‑year revenue decline driven by a shrinking Behavioral base undermines scale economics and raises per‑unit acquisition costs. Heavy reliance on converting a legacy cohort to higher‑value offerings creates execution risk and increases marketing needs to stabilize top‑line growth over the medium term.
Read all positive and negative factors
Positive Factors
Negative Factors
Clinical subscription growth & ARPU expansion
Sustained mix shift toward higher‑value Clinical subscribers and rising ARPU improves revenue per user and long‑run unit economics. As Clinical becomes a larger revenue share, the business can offset Behavioral declines, support margin expansion and increase lifetime value through upsells and tailored programs.
Read all positive factors
WW International, Inc. (WW) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$159.78M
Dividend YieldN/A
Average Volume (3M)401.30K
Price to Earnings (P/E)0.1
Beta (1Y)1.43
Revenue Growth-9.61%
EPS GrowthN/A
CountryUS
Employees3,700
SectorConsumer Cyclical
Sector Strength84
IndustryPersonal Products & Services
Share Statistics
EPS (TTM)3.40
Shares Outstanding9,998,760
10 Day Avg. Volume365,138
30 Day Avg. Volume401,303
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)0.92
Price to Sales (P/S)0.41
P/FCF Ratio-6.30
Enterprise Value/Market Cap3.18
Enterprise Value/Revenue0.73
Enterprise Value/Gross Profit1.07
Enterprise Value/Ebitda0.41
Forecast
1Y Price Target
$20.00Price Target Upside-8.63% Downside
Rating ConsensusHold
Number of Analyst Covering1
EPS Forecast (FY)-4.2
Revenue Forecast (FY)$632.19M
WW International, Inc. Business Overview & Revenue Model
Company Description
WW International, Inc. provides weight management products and services worldwide. The company operates in four segments: North America, Continental Europe, United Kingdom, and Other. It offers a range of nutritional, activity, behavioral, and lif...
How the Company Makes Money
WW primarily generates revenue by selling subscriptions to its weight-management and wellness programs. The core revenue stream has historically been recurring membership fees for digital access (e.g., app-based plans and online tools), where cust...
WW International, Inc. Earnings Call Summary
Earnings Call Date:May 07, 2026
(Q1-2026)
| % Change Since: |
Next Earnings Date:Jul 30, 2026
Earnings Call Sentiment Neutral
The call presents a balanced picture: clear operational and strategic positives driven by rapid Clinical growth, improving ARPU, strong program outcomes, high adjusted gross margins and reaffirmed full-year guidance. Offsetting these gains are meaningful declines in Behavioral subscribers and Behavioral revenue, a quarter with a small EBITDA loss and a front-loaded marketing spend that reduced cash in Q1. Management is executing a deliberate multiyear transformation, and while early signs are encouraging, near-term risks (subscriber base mix shift, marketing cadence, interest costs and legacy compounding churn) temper the outlook.Positive Updates
Strong Clinical Growth and Improving Revenue Mix
Clinical subscription revenue grew 32% year-over-year; end-of-period Clinical subscribers grew 46% year-over-year and reached 197,000 (a 51% sequential increase). Management expects Clinical subscription revenue to comprise ~25%–30% of 2026 revenue, up from 16% in 2025.
Negative Updates
Large Decline in Behavioral Subscribers
End-of-period Behavioral subscribers were 2.5 million, a 25% year-over-year decline. Behavioral subscription revenue declined 17% year-over-year, reflecting secular headwinds in the Core Behavioral offering and deliberate marketing prioritization of Med+.
Read all updates
Q1-2026 Updates
Positive
Negative
Strong Clinical Growth and Improving Revenue Mix
Clinical subscription revenue grew 32% year-over-year; end-of-period Clinical subscribers grew 46% year-over-year and reached 197,000 (a 51% sequential increase). Management expects Clinical subscription revenue to comprise ~25%–30% of 2026 revenue, up from 16% in 2025.
Read all positive updates
Company Guidance
WeightWatchers reaffirmed 2026 guidance of $620–$635 million in revenue and $105–$115 million of adjusted EBITDA and said it expects to generate cash in 2026; it expects Clinical subscription revenue to be ~25%–30% of 2026 revenue (up from 16% in 2025), adjusted gross margin to remain above 72% (Q1 was 73.6%), and sequential Clinical subscriber growth through the year though with lower net adds than Q1 (after ending Q1 with 197k Clinical subscribers and 537k Core+); the company expects marketing spend as a percent of revenue to increase modestly vs 2025, product development to stay at a similar run rate to Q1 (~5% of revenue), modest SG&A savings, ~ $45–50 million of interest expense in 2026, CapEx at a similar quarterly run rate to Q1 (Q1 CapEx $6M), and cash taxes of $5–10 million, while noting Q1 revenue was $168 million, Q1 ARPU was $20.59 (+13% YoY), Q1 adjusted EBITDA was a loss of $1.8 million, ending cash was $121 million (down from $160M), and it plans a Q2 $37 million cash paydown to reduce term loan principal by $42 million (term loan rate ~10.5% as of 3/31/26) to lower annualized interest by ~ $4 million.WW International, Inc. Financial Statement Overview
Summary
Income Statement
58
Neutral
Balance Sheet
52
Neutral
Cash Flow
34
Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 692.33M | 710.64M | 785.92M | 889.55M | 1.04B | 1.21B |
| Gross Profit | 475.43M | 510.50M | 533.10M | 529.30M | 621.38M | 726.67M |
| EBITDA | 1.24B | 1.22B | -198.44M | 74.73M | -241.86M | 213.44M |
| Net Income | 1.08B | 1.06B | -345.70M | -112.25M | -256.87M | 67.13M |
Balance Sheet | ||||||
| Total Assets | 881.07M | 946.76M | 550.28M | 982.03M | 1.03B | 1.43B |
| Cash, Cash Equivalents and Short-Term Investments | 126.67M | 160.28M | 53.02M | 109.37M | 178.33M | 153.79M |
| Total Debt | 468.19M | 468.62M | 1.48B | 1.49B | 1.51B | 1.52B |
| Total Liabilities | 615.50M | 628.69M | 1.66B | 1.74B | 1.71B | 1.89B |
| Stockholders Equity | 265.57M | 318.07M | -1.11B | -761.09M | -685.78M | -456.40M |
Cash Flow | ||||||
| Free Cash Flow | -82.95M | -46.38M | -33.25M | -29.61M | 38.39M | 119.63M |
| Operating Cash Flow | -65.93M | -28.90M | -16.84M | 6.69M | 76.65M | 157.28M |
| Investing Cash Flow | -22.31M | -19.50M | -16.41M | -74.70M | -42.64M | -52.75M |
| Financing Cash Flow | -17.35M | 153.90M | -17.34M | -2.75M | -4.72M | -111.54M |
WW International, Inc. Risk Analysis
WW International, Inc. disclosed 40 risk factors in its most recent earnings report. WW International, Inc. reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
WW International, Inc. Peers Comparison
UnderperformOutperform
Sector (61)
WW
WW International, Inc.
16.13
-14.07
-46.59%
MED
Medifast
12.24
-1.30
-9.60%
MRM
MEDIROM Healthcare Technologies
1.19
-0.33
-21.71%
WW International, Inc. Corporate Events
Business Operations and StrategyFinancial DisclosuresPrivate Placements and Financing
WW International Announces Term Loan Prepayment and Deleveraging Plan
Positive
Apr 27, 2026
On April 27, 2026, WW International, Inc. announced plans to use up to $40 million in cash to prepay and reduce the principal on its outstanding term loan, signaling a continued push to deleverage its balance sheet. The move blends a $25 million t...
Business Operations and StrategyExecutive/Board Changes
WW International Adds Heather Thiltgen to Board
Positive
Apr 20, 2026
On April 19, 2026, the board of WW International unanimously elected Heather Thiltgen as an independent director, effective April 20, 2026, expanding the board from five to six members, all independent. She will serve until the 2026 annual meeting...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.